Home › Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen
 

Keywords :   


Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen

2015-05-07 14:30:00| Merck.com - Product News

Dateline City: BERKELEY, Calif., and KENILWORTH, N.J. Study will Evaluate Mercks Anti-PD-1 Therapy, KEYTRUDA (pembrolizumab), in Combination with Plexxikons PLX3397 BERKELEY, Calif., and KENILWORTH, N.J. May 7, 2015 Plexxikon Inc., a member of Daiichi Sankyo Group, and Merck (NYSE:MRK), known as MSD outside the US and Canada, through a subsidiary, today announced a collaborative clinical trial that will evaluate the combination of PLX3397, Plexxikons investigational CSF-1R inhibitor, and KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, which provides the potential for a double blockade of cancer-induced immune suppression. Language: English read more

Tags: study combination evaluating collaborate

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.07Atlantic Tropical Weather Outlook
06.07Tropical Storm Beryl Public Advisory Number 30A
06.07Summary for Tropical Storm Beryl (AT2/AL022024)
06.07Eastern North Pacific Tropical Weather Outlook
06.07Tropical Storm Beryl Potential Storm Surge Flooding Map
06.07Tropical Storm Beryl Probabilistic Storm Surge Graphics
06.07Tropical Storm Beryl Forecast Discussion Number 30
06.07Tropical Storm Beryl Graphics
More »